title: Establishment and characterization of two new cell lines derived from human metastatic breast carcinomas.
abstract: Two human cancer cell lines (MA 2 and MA 3) were established from pleural effusions of infiltrating ductal carcinomas of the breast. The lines were maintained in continuous monolayer culture with doubling times of 70 (MA 2) and 78 (MA 3) hr for more than two years and possessed extensively rearranged abnormal karyo-types with modal chromosome number of 83 (MA 2) and 81 (MA 3) and DNA index values of 1.65 and 1.77, respectively. No amplifications or rearrangements were evident in the c-myc, int-2, c-erb B2, c-Ha-ras, or hst 1 genes in MA 2 and MA 3 cell lines. The clinical histories of the patients from whom the cell lines were derived are reported and compared with the results observed in the cell lines in vitro. The presence of CEA, CA 15-3, and MCA tumor markers observed in the primary tumor tissues was retained by the established cell lines. While the primary tumor tissues were ER+/PgR borderline+ (MA 2) and ER-/PgR+ (MA 3), the MA 2 line was ER+/PgR- and the MA 3 line remained ER-/PgR+. The MDR P-glycoprotein was not expressed either in primary tumor tissues or in the respective cell lines. High expression of cytokeratins 7, 18, and 19 was evident by immunohistochemical analysis in each cell line. whereas cytokeratins 8 and 17 were poorly or not at all expressed. The treatment history of the patients from whom the cell lines were derived involved CMF followed six months later by novantrone and cisplatin plus VP 16 (MA 2) and FEC followed four years later by CMF (MA 3). The chemosensitivity pattern assay of the cell lines indicated that the MA 2 line was sensitive to doxorubicin, cisplatin, and vinblastine, whereas the MA 3 line was sensitive to doxorubicin and cisplatin. The characteristics of these cell lines indicate them to be a good experimental model to investigate breast cancer biology and anticancer drug response.
authors.affiliation: Department of Medical Oncology, Morgagni-Pierantoni Hospital, Forli, Italy.
authors.forename: W
authors.initials: W
authors.lastname: Zoli
authors.forename: L
authors.initials: L
authors.lastname: Roncuzzi
authors.forename: N
authors.initials: N
authors.lastname: Zini
authors.forename: L
authors.initials: L
authors.lastname: Lenzi
authors.forename: R
authors.initials: R
authors.lastname: Gruppioni
authors.forename: F
authors.initials: F
authors.lastname: Barzanti
authors.forename: A
authors.initials: A
authors.lastname: Sensi
authors.forename: D
authors.initials: D
authors.lastname: Amadori
authors.forename: A
authors.initials: A
authors.lastname: Gasperi-Campani
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D002455:Cell Division / Q000502:physiology; D004273:DNA, Neoplasm / Q000235:genetics; D004354:Drug Screening Assays, Antitumor; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D007621:Karyotyping; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011519:Proto-Oncogenes; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000473:pathology
chemical_list: D004273:DNA, Neoplasm